
|Articles|December 11, 2003
LHRH litigation will go forward, court rules
A U.S. District Judge has sustained plaintiff's complaint against the manufacturers of the LHRH agonist leuprolide acetate (Lupron), for improper pricing activities.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Theranostic therapies expand frontline use in prostate cancer
2
FDA removes warning labels on hormone replacement therapy
3
BioProtect Balloon Spacer shows sustained quality-of-life benefits in long-term study
4
Apalutamide vs Abiraterone Acetate RWE Outcomes in mCSPC
5



















